Codexis Announces Appointment of Margaret Fitzgerald as Chief Legal Officer and General Counsel
REDWOOD CITY, Calif., Nov. 01, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment of Margaret (“Meg”) Fitzgerald as Chief Legal Officer and General Counsel, effective immediately. In this role, Ms. Fitzgerald will lead the Company’s legal and compliance functions and provide strategic guidance to the Board of Directors and executive management team. She will report directly to Dr. Stephen Dilly, President and CEO of Codexis.
“Meg is a seasoned legal executive and leader with extensive experience on both routine and complex legal matters,” said Dr. Dilly. “Meg brings invaluable legal and business expertise across product development, commercial launches, compliance, and intellectual property. I am excited to welcome Meg to the team. Meg’s skill set will prove critical as we continue to grow our business.”
“I am delighted to join Codexis at this exciting time in the Company’s development and I look forward to building upon the team’s many accomplishments,” said Ms. Fitzgerald. “Codexis is a leader in the enzyme engineering space, and I am honored to work alongside this talented executive team as we continue delivering meaningful innovations across our core target markets.”
Ms. Fitzgerald brings over twenty years of experience across the biotechnology industry. Most recently, she served as General Counsel, Corporate Secretary and Chief Compliance Officer at Allakos, Inc., where she provided strategic legal advice on securities, litigation, IP strategy, clinical development, and commercialization. Prior to Allakos, Ms. Fitzgerald was Associate General Counsel and Privacy Officer at Aimmune Therapeutics, Inc. Previously, she served as Vice President of Corporate Law at ZS Pharma, Inc., where she chaired negotiations, resulting in the $2.7 billion sale of ZS Pharma to AstraZeneca. Earlier in her career, Ms. Fitzgerald held increasingly senior leadership roles at Genentech, Inc., ultimately serving as Associate General Counsel and Director of Transactional Law. Ms. Fitzgerald also served as an Associate Attorney at Pillsbury Winthrop Shaw Pittman. She holds a J.D. from University of California, Berkeley, as well as an M.A. and a B.A. in History from Stanford University.
Codexis is a leading enzyme engineering company leveraging its proprietary CodeEvolver® platform to discover and develop novel, high performance enzymes and biotherapeutics. Codexis enzymes have applications in the sustainable manufacturing of pharmaceuticals, food, and industrial products; in the creation of the next generation of life science tools; and as gene therapy and oral enzyme therapies. The Company’s unique performance enzymes drive improvements such as: reduced energy usage, waste generation and capital requirements; higher yields; higher fidelity diagnostics; and more efficacious therapeutics. Codexis enzymes enable the promise of synthetic biology to improve the health of people and the planet. For more information, visit www.codexis.com.
To the extent that statements contained in this press release are not descriptions of historical facts regarding Codexis, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You should not place undue reliance on these forward-looking statements because they involve known and unknown risks, uncertainties and other factors that are, in some cases, beyond Codexis’ control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexis’ Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on February 28, 2022 and in Codexis’ Quarterly Report on Form 10-Q filed with the SEC on August 5, 2022, including under the caption “Risk Factors,” and in Codexis’ other periodic reports filed with the SEC. Codexis expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Investor Relations Contact:
Brendan Strong/Carrie McKim
Released November 1, 2022